Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22
Open Access
- 7 February 2008
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 140 (5), 527-536
- https://doi.org/10.1111/j.1365-2141.2007.06964.x
Abstract
Hodgkin lymphoma (HL) is characterized by a minority of neoplastic Hodgkin‐Reed Sternberg (HRS) cells surrounded by a non‐neoplastic reactive infiltrate. As immunological mechanisms appear to be crucial in classical HL pathogenesis, altered serum chemokine levels might be related to disease activity. Serum levels of nine chemokines were examined in 163 untreated HL patients and 334 controls. We investigated single nucleotide polymorphisms (SNPs) for association with serum CCL17 (thymus and activation‐regulated chemokine, TARC) levels and HL susceptibility. Serum CCL17 and CCL22 (macrophage‐derived chemokine, MDC) levels were significantly increased in 82% and 57% of the HL patients. Nodular sclerosis cases showed increased serum CCL17 and CCL22 levels (P < 0·001) and serum levels were correlated with Ann Arbor stage. Of nine patients with pre‐ and post‐treatment serum samples, the majority showed decreased CCL17 and CCL22 levels after treatment. HRS cells expressed CCL17 and CCL22 in 77% and 75% of 74 cases. Three SNPs showed a trend of increased serum CCL17 levels with minor alleles in controls, but were not associated with HL susceptibility. CCL17 and CCL22 were the only chemokines with increased serum levels in the vast majority of HL patients, which provides further insight into the molecular mechanism(s) leading to infiltrations of reactive lymphocytes in HL.Keywords
This publication has 31 references indexed in Scilit:
- Specific Recruitment of CC Chemokine Receptor 4–Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune PrivilegeCancer Research, 2006
- Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed–Sternberg (HRS) cells: high expression of interleukin-11 receptor αAnnals Of Oncology, 2005
- Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphomaThe Lancet, 2005
- Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitisJournal of Allergy and Clinical Immunology, 2004
- Expression of CCL5/RANTES by Hodgkin and Reed‐Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissueInternational Journal of Cancer, 2003
- Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoidesJournal of the American Academy of Dermatology, 2003
- Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomasInternational Journal of Cancer, 2002
- Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's diseaseThe Journal of Pathology, 2001
- The Reed–Sternberg cell in classical Hodgkin's diseaseHematological Oncology, 2001
- High Expression of the CC Chemokine TARC in Reed-Sternberg CellsThe American Journal of Pathology, 1999